MOTIVATION LETTER The opioid crisis in West Africa is understudied and underfunded, yet Nigeria has one of the highest rates of prescription opioid misuse on the continent. My independent research has produced a validated computational framework, the Conjunctive Consolidation Threshold (CCT) model, that predicts how pharmacological agents can prevent reward-memory encoding during addiction. Three sole-authored preprints on OSF and Zenodo document the model: a foundational paper (OSF 10.17605/OSF.IO/KG7B5), a formal mathematical specification (OSF 10.17605/OSF.IO/EMY4U), and a Bayesian population dynamics and clinical trial architecture (Zenodo 10.5281/zenodo.20492472). ODE/RK45 and Bayesian MCMC validation demonstrated an encoding probability reduction from 0.855 to 0.122, an 85.8% reduction, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol (Elsevier). This R01 application to the National Institutes of Health proposes to extend the CCT model into a translational bioinformatics pipeline that screens existing and novel compounds for their ability to disrupt reward-memory consolidation. The provisional patent on the CCT core architecture, filed Q3 2026, protects the computational core. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific credibility of the framework. The IMPRINT platform, which I built, screens for addiction liability using the CCT logic. The TOPOLOGIX platform applies topological data analysis, persistent homology and bipartite simplicial complexes, to drug-protein interaction networks, with a validated hERG cardiotoxicity MVP. The GATE platform evaluates BCI neural-stimulation safety under Apache 2.0. Nigeria offers a unique population for studying addiction in a context of polypharmacy, limited regulatory oversight, and high genetic diversity. My position as National Product Manager at Synthcare and my prior clinical pharmacy work at Ramset Pharmacy provide direct access to patient-level prescription data and clinical workflows. The NIH mission to address health disparities and global health aligns directly with this proposal. I am applying for the R01 as an independent researcher based in Lagos, with plans to enroll in an MSc at Medical University of Graz starting October 2026. This grant would fund the computational infrastructure, data collection in Lagos, and collaboration with my endorsers for model validation. RESEARCH STATEMENT The Conjunctive Consolidation Threshold (CCT) model posits that reward-memory encoding in addiction requires the simultaneous activation of three neural systems: dopaminergic reward signaling, glutamatergic memory consolidation, and noradrenergic arousal. Pharmacological intervention at any two of these three nodes, applied within a critical temporal window, prevents the encoding of drug-context associations. The model is formally specified as a system of ordinary differential equations with a conjunctive threshold function, solved using RK45 integration. Bayesian MCMC estimation, implemented in PyMC, fitted the model to simulated population data and produced posterior distributions confirming the super-additive effect of dual-node blockade. Preliminary data from the three preprints show that the encoding probability drops from 0.855 under single-agent conditions to 0.122 under dual-node blockade, a reduction of 85.8%. The super-additive effect of 12.8 percentage points exceeds the sum of individual effects, confirming the conjunctive mechanism. All five pre-registered hypotheses, H1 through H5, were confirmed at a significance threshold of p < 0.01. The provisional patent filed Q3 2026 covers the core architecture of the CCT model, including the mathematical formulation and the clinical trial design. This R01 proposal will achieve four specific aims. Aim 1: Extend the CCT model to incorporate pharmacokinetic-pharmacodynamic (PK/PD) parameters for 50 FDA-approved compounds, using RDKit for molecular descriptors and ADMET/QSAR for toxicity prediction. Aim 2: Validate the model predictions using the TOPOLOGIX platform, applying persistent homology to drug-protein interaction networks derived from AlphaFold structures and AutoDock docking scores. Aim 3: Deploy the IMPRINT screening platform in a cohort of 200 patients at Ramset Pharmacy and Synthcare clinical sites in Lagos, collecting prescription records, self-reported craving scores, and urine toxicology data over six months. Aim 4: Run a Bayesian adaptive clinical trial simulation using the architecture from Zenodo 10.5281/zenodo.20492472, testing three dual-node combinations against placebo and single-agent controls. The computational infrastructure will use Python with scipy, numpy, PyMC, and pandas for modeling; Ripser and Gudhi for topological data analysis; NEURON and Brian2 for neural simulation; and Nextflow with SLURM for HPC workflow management. Data will be stored in Supabase/Postgres with a JavaScript/Node.js frontend for clinical data entry. The GATE platform will evaluate any BCI-related safety endpoints if neural-stimulation components are added in later phases. The Africa/Nigeria angle is central. No published CCT-type model has been tested in a West African population. The genetic diversity, high prevalence of opioid misuse, and limited access to addiction treatment create a natural experiment for testing the model's generalizability. My collaborators, Berridge, Gershman, Daw, and Mattar, have agreed to provide computational and theoretical oversight. The NIH R01 mechanism, with its emphasis on translational bioinformatics and health disparities, is the appropriate vehicle for this work. BUDGET JUSTIFICATION Personnel: 50% effort for Eniola Olutogun as Principal Investigator for 12 months. Salary based on current National Product Manager rate at Synthcare. No other personnel requested. Equipment: One HPC workstation with 64-core AMD Threadripper, 256 GB RAM, 4 TB NVMe SSD, and NVIDIA RTX 4090 GPU for ODE/RK45 simulations, Bayesian MCMC sampling, and TDA computations. Cost: $12,000. Computational Services: AWS EC2 spot instances for parallel MCMC chains and AlphaFold structure prediction. Estimated 10,000 compute hours at $0.04/hour. Cost: $400. Software Licenses: PyMC, Gudhi, RDKit, and GROMACS are open-source. No license costs. Travel: Two trips to collaborators' labs: one to University of Michigan (Berridge) and one to Harvard (Gershman). Airfare, lodging, and per diem at NIH rates. Cost: $6,000. Materials and Supplies: Python packages, data storage, and cloud database hosting on Supabase. Cost: $500. Publication Costs: Open-access fees for two papers in journals indexed in PubMed Central. Cost: $4,000. Total Direct Costs: $22,900. Indirect costs at 8% for independent researcher: $1,832. Total Request: $24,732. TIMELINE Months 1-3: Extend CCT model with PK/PD parameters for 50 compounds. Run RDKit and ADMET/QSAR screening. Begin TOPOLOGIX persistent homology analysis on drug-protein interaction networks. Months 4-6: Deploy IMPRINT platform at Ramset Pharmacy and Synthcare clinical sites. Enroll first 100 patients. Collect baseline prescription records and craving scores. Months 7-9: Complete enrollment of 200 patients. Run Bayesian adaptive clinical trial simulation using the Zenodo architecture. Analyze TOPOLOGIX results. Months 10-12: Final data analysis. Write two manuscripts for submission to peer-reviewed journals. Prepare final report for NIH. Submit continuation application if warranted. CHECKLIST - [ ] Completed SF424 (R&R) application form - [ ] Project Summary/Abstract (30 lines max) - [ ] Project Narrative (3 sentences) - [ ] Research Strategy (12 pages max): includes Significance, Innovation, Approach - [ ] Bibliography and References Cited - [ ] Biographical Sketch for Eniola Olutogun (5 pages max, NIH format) - [ ] Budget and Budget Justification (as above) - [ ] Facilities and Other Resources description - [ ] Equipment description - [ ] Data Sharing Plan - [ ] Authentication of Key Biological and/or Chemical Resources plan - [ ] Letters of Support from Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar - [ ] Provisional patent documentation (Q3 2026 filing) - [ ] Preprint DOIs: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472 - [ ] Proof of PCN pharmacist license - [ ] Proof of B.Pharm degree from University of Ibadan - [ ] ORCID iD: 0009-0001-9272-6735 - [ ] GitHub repository links: github.com/AmunRaPtah - [ ] ZYCO organization profile: zyco.org EDITOR NOTES - Eligibility risk: The R01 is typically for established investigators with a PhD or MD. Eniola holds a B.Pharm and is not yet enrolled in an MSc. The application must explicitly justify why an independent researcher without a doctoral degree is appropriate for this mechanism. Consider adding a section on "Career Stage Justification" or applying under the "Early Stage Investigator" designation if NIH allows for non-doctoral PIs. Verify NIH policy on PI eligibility for R01 without a doctoral degree. - Fact verification needed: The provisional patent filing date is listed as "Q3 2026." Confirm the exact filing date and patent application number. The NIH requires documentation of intellectual property. If the patent has not yet been filed, adjust the timeline and language accordingly. - Gap in personal detail: The profile does not specify whether Eniola has a formal affiliation with a U.S. institution. The R01 requires a U.S.-based institution or a foreign institution with a U.S. partner. If Eniola remains based in Lagos, the application must include a detailed Foreign Institution Justification. Alternatively, consider listing a U.S. collaborator's institution as the applicant institution with Eniola as a subcontractor. Clarify this before submission. - Missing data on Nigerian addiction prevalence: The proposal claims Nigeria has high opioid misuse rates but provides no citation. Include a reference to the 2023 Nigerian National Drug Use Survey or the UNODC World Drug Report for West Africa. This strengthens the health disparities angle. - Budget realism: The total request of $24,732 is very low for an R01. Typical R01 budgets exceed $250,000 per year. While this may be appropriate for a small independent project, the NIH may question whether the scope matches the budget. Consider scaling up the budget to include a postdoctoral researcher or a data analyst, or explicitly state that this is a pilot/feasibility phase with a larger R01 to follow.